Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T18:55:39.840Z.
Calculation as of: 2026-10-06T18:55:39.840Z.
Quote observation: 2026-10-06T18:55:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$759.02M
EV/Sales Ratio
3.32x
TTM Avg
2.72x
3Y Avg
3.17x
5Y Avg
4.51x
Market Cap
$764.21M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$777.61M
EV/Sales Ratio
19.19x
TTM Avg
12.42x
3Y Avg
202.88x
5Y Avg
983.65x
Market Cap
$735.63M
EV/Sales Ratio
N/A
TTM Avg
777.64x
3Y Avg
653.12x
5Y Avg
653.12x
Market Cap
$732.76M
EV/Sales Ratio
N/A
TTM Avg
0.38x
3Y Avg
0.82x
5Y Avg
6.17x
Market Cap
$778.22M
EV/Sales Ratio
1.22x
TTM Avg
0.95x
3Y Avg
1.06x
5Y Avg
1.24x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apnimed, Inc. (APMD) | $754.65M | N/A | N/A | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $750.73M | N/A | N/A | N/A | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $759.02M | 3.32x | 2.72x | 3.17x | 4.51x |
| Attovia Therapeutics, Inc. (ATTO)vs › | $764.21M | N/A | N/A | N/A | N/A |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $777.61M | 19.19x | 12.42x | 202.88x | 983.65x |
| Candel Therapeutics, Inc. (CADL)vs › | $735.63M | N/A | 777.64x | 653.12x | 653.12x |
| Achieve Life Sciences, Inc. (ACHV)vs › | $732.76M | N/A | 0.38x | 0.82x | 6.17x |
| Varex Imaging Corporation (VREX)vs › | $778.22M | 1.22x | 0.95x | 1.06x | 1.24x |
| Sana Biotechnology, Inc. (SANA)vs › | $783.39M | N/A | N/A | N/A | N/A |
| AdaptHealth Corp. (AHCO)vs › | $785.71M | 0.93x | 1.16x | 1.13x | 1.47x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
